Anti-HSV-1 agents: an update
Herpes simplex virus type I (HSV-1) is a member of the α-herpesvirus subfamily and is capable of causing herpes simplex keratitis, herpes labialis, and herpes simplex encephalitis. HSV-1 is well known for its lytic infections at the primary sites and for establishing latency in the sensory neuronal...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1451083/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832584868725260288 |
|---|---|
| author | Wenwen Lv Lei Zhou Jia Wu Jishuai Cheng Yongzhong Duan Wen Qian |
| author_facet | Wenwen Lv Lei Zhou Jia Wu Jishuai Cheng Yongzhong Duan Wen Qian |
| author_sort | Wenwen Lv |
| collection | DOAJ |
| description | Herpes simplex virus type I (HSV-1) is a member of the α-herpesvirus subfamily and is capable of causing herpes simplex keratitis, herpes labialis, and herpes simplex encephalitis. HSV-1 is well known for its lytic infections at the primary sites and for establishing latency in the sensory neuronal ganglia, with occasional recurrent infections. To date, there are no approved commercially available vaccines, and anti-HSV-1 drugs such as specific or non-specific nucleotide (nucleoside) analogs and helicase-primase inhibitors have become the main clinical agents for the treatment of HSV-1 infections despite challenges from resistance. Therefore, development of new anti-HSV-1 compounds or therapies is key to addressing the issue of resistance. The present review provides an update on the progress made over approximately 60 years regarding anti-HSV-1 agents while also highlighting future perspectives for controlling HSV-1 infections. |
| format | Article |
| id | doaj-art-73dd52237fd44bc9a3bbd80fae1375d2 |
| institution | Kabale University |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-73dd52237fd44bc9a3bbd80fae1375d22025-01-27T10:42:21ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-01-011510.3389/fphar.2024.14510831451083Anti-HSV-1 agents: an updateWenwen Lv0Lei Zhou1Jia Wu2Jishuai Cheng3Yongzhong Duan4Wen Qian5College of Pharmaceutics, Kunming Medical University, Kunming, ChinaCollege of Pharmaceutics, Kunming Medical University, Kunming, ChinaCollege of Basic Medical, Kunming Medical University, Kunming, ChinaDepartment of Experimental Animals, Kunming Medical University, Kunming, ChinaAcademy of Biomedical Engineering, Kunming Medical University, Kunming, ChinaWalvax Biotechnology Co., Ltd., Kunming, Yunnan, ChinaHerpes simplex virus type I (HSV-1) is a member of the α-herpesvirus subfamily and is capable of causing herpes simplex keratitis, herpes labialis, and herpes simplex encephalitis. HSV-1 is well known for its lytic infections at the primary sites and for establishing latency in the sensory neuronal ganglia, with occasional recurrent infections. To date, there are no approved commercially available vaccines, and anti-HSV-1 drugs such as specific or non-specific nucleotide (nucleoside) analogs and helicase-primase inhibitors have become the main clinical agents for the treatment of HSV-1 infections despite challenges from resistance. Therefore, development of new anti-HSV-1 compounds or therapies is key to addressing the issue of resistance. The present review provides an update on the progress made over approximately 60 years regarding anti-HSV-1 agents while also highlighting future perspectives for controlling HSV-1 infections.https://www.frontiersin.org/articles/10.3389/fphar.2024.1451083/fullHSV-1antiviralagentsimmunomodulationherpes virus |
| spellingShingle | Wenwen Lv Lei Zhou Jia Wu Jishuai Cheng Yongzhong Duan Wen Qian Anti-HSV-1 agents: an update Frontiers in Pharmacology HSV-1 antiviral agents immunomodulation herpes virus |
| title | Anti-HSV-1 agents: an update |
| title_full | Anti-HSV-1 agents: an update |
| title_fullStr | Anti-HSV-1 agents: an update |
| title_full_unstemmed | Anti-HSV-1 agents: an update |
| title_short | Anti-HSV-1 agents: an update |
| title_sort | anti hsv 1 agents an update |
| topic | HSV-1 antiviral agents immunomodulation herpes virus |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2024.1451083/full |
| work_keys_str_mv | AT wenwenlv antihsv1agentsanupdate AT leizhou antihsv1agentsanupdate AT jiawu antihsv1agentsanupdate AT jishuaicheng antihsv1agentsanupdate AT yongzhongduan antihsv1agentsanupdate AT wenqian antihsv1agentsanupdate |